Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model.

Johannes Falke,Christina A Hulsbergen-van de Kaa,Roberto Maj,Egbert Oosterwijk,Johannes Alfred Witjes

Urologic Oncology: Seminars and Original Investigations（2018）

引用 2|浏览22

暂无评分

摘要

•TLR-7 agonists are under investigation for treatment of urothelial carcinoma.•TMX-101 and TMX-202 are TLR-7 agonists suitable for intravesical administration.•Both drugs demonstrated a good safety profile in this preclinical rat study.•Intravesical instillation of TMX-202 showed less systemic uptake compared to TMX-101.

查看译文

关键词

Immune modulator,Imiquimod,Non–muscle-invasive bladder cancer,Pharmacodynamics,Pharmacokinetics,Toll-like receptor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要